The Aleuria aurantia lectin (AAL) derived from orange peel fungus contains five fucosebinding sites that recognizes fucose bound in ␣-1,2, ␣-1,3, ␣-1,4, and ␣-1,6 linkages to N-acetylglucosamine and galactose. Recently, we have created several recombinant AAL (rAAL) proteins that had altered binding affinity to fucose linkages. In this report, we further characterize the binding specificity of one of the mutated lectins, N224Q lectin. This lectin was characterized by lectin Western blotting, surface plasmon resonance, and glycan microarray and shown to have increased binding to fucosylated glycan. Subsequently, we used this lectin to identify secreted fucosylated glycoproteins from a fetal hepatic cell line. Proteomic analysis revealed several glycoproteins secreted by the fetal cell line that were bound by N224Q lectin. These findings were confirmed by subsequent proteomic analysis of human serum from control patients or patients with hepatocellular carcinoma. These represent candidate oncofetal markers for liver cancer.
Introduction
Asparagine (N)-linked glycosylation of secreted and membrane proteins is a common PTM. Both broad changes in the assembled glycan side chains as well as more specific changes to the glycosylation of individual proteins have been associated with diseases such as cancer [1] . For instance, fucosylation of N-linked glycans has been associated with several types of cancer [2] . An increase in the addition of core ␣-1,6-linked fucose and ␣-1,3 outer-arm fucose is associated with the development of hepatocellular carcinoma (HCC) [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Several of the proteins containing increased fucose have been identified and characterized as potential biomarkers of HCC.
Significance of the study
Hepatocellular carcinoma (HCC) is one of the fastest rising cancers in the United States, in both incidence and mortality and remains one of the leading causes of cancer-related death worldwide. Early detection of this cancer is essential to reduce the mortality associated with this cancer. As many cancer biomarkers are fetal in origin, we have utilized a fetal cell line to identify glycan changes that are associated with fetal liver tissue. Subsequently, using a novel recombinant lectin, we have performed glycoproteomics and identified several of the glycoproteins that contain the glycan associated with the fetal tissue. Last, we have validated the identified biomarkers through the subsequent analysis of human sera from those with HCC. Studies are underway to determine the ability of these proteins to act as biomarkers of HCC.
In plate-based assays, the Aleuria aurantia lectin (AAL) was used to detect fucosylation of antibody captured proteins.
Native AAL has five binding pockets for the sugar, each formed between adjacent domains of a six-bladed ␤-propeller [17] [18] [19] [20] . Different sites bind to multiple fucose linkages, including ␣-1,2, ␣ -1,3, ␣ -1,4 as well as core ␣-1,6-fucose [17, 18] . However, it is thought that the multiple fucose-binding sites of the lectin display differential specificity with respect to the linkages that can bind. We used structural information to re-engineer the wild-type lectin, and in this report, characterized the binding of this lectin to fucosylated glycan [21] .
Subsequently, as many cancer biomarkers are fetal in origin, we have used this recombinant lectin as an affinity reagent to perform glycoproteomics in an effort to identify potential glycoproteins with altered fucosylation and confirmed the identification of those proteins via a human proteomic analysis of control or HCC serum following extraction with a known core fucose-binding lectin.
Materials and methods

Materials
AAL was purchased from Vector Laboratories (Burlingame, CA, USA). PNGase F PRIME was obtained from Bulldog Bio (Portsmouth, NH, USA). ChromPure whole molecule of human IgG was purchased from Jackson ImmunoResearch Labs Inc. (West Grove, PA, USA). BSA-fucose and BSA-galactose were purchased from Vector Laboratories, Inc. (Burlingame, CA, USA). Human cord serum alphafetoprotein (AFP) was purchased from Lee Biosolutions, Inc. (Maryland Heights, MO, USA). Recombinant AAL (rAAL) 10 histidine (10XHis) and N224Q were synthesized in-house using protocols described previously [21] . Reagents used in glycan array were provided by the Consortium for Functional Glycomics (CFG) under Glue Grant No. R24 GM098791 from the NIH. The PureProteomeۛ nickel magnetic bead system was purchased from EMD Millipore (Billerica, MA, USA). The fetal liver hepatocyte cBAL111 cells were a gift from Dr. Ruurdtje Hoekstra, Academic Medical Center, Amsterdam, the Netherlands. Normal primary human hepatocytes in suspension were obtained through the Liver Tissue Cell Distribution System (Pittsburgh, PA, USA), funded by NIH Contract No. HHSN276201200017C. All cell culture media and supplements were purchased from Corning (Corning, NY, USA) unless otherwise indicated. Exoglycosidase enzymes Glyko
)-Galactosidase, and Glyko R Sialidase A TM were purchased from ProZyme (Hayward, CA, USA). The HyperSep Hypercarb graphite carbon columns were purchased from Thermo Fisher Scientific (Waltham, MA, USA). The TSKgel Amide-80 column was from Tosoh Bioscience LLC (King of Prussia, PA, USA). HPLC chromatograms were acquired on a Waters Alliance HPLC system complemented with a Waters fluorescence detector and Millenium Chromatography Manager software for quantification (Milford, MA, USA). All other reagents and chemicals were purchased and used from Sigma (St. Louis, MO, USA).
Patient samples
Diseased human serum was obtained from our clinical collaborator at the Saint Louis University School of Medicine (St. Louis, MO, USA). These samples were collected via a study protocol approved by the Saint Louis University Institutional Review Board, and written informed consent was obtained from each subject. Demographic and clinical information is found in a prior publication [9] .
Recombinant lectin expression and peptide synthesis
Complete and detailed methods regarding both rAAL with a 10XHis tag at the C-terminus and rAAL containing an asparagine (N) to glutamine (Q) mutation (N224Q) plasmid construction, and protein expression and purification are described previously by Romano et al. [21] . The Pholiota squarrosa lectin (PhoSL) with N-terminal biotin was synthesized by CPC Scientific (Sunnyvale, CA, USA) using the amino acid sequence from Kobayashi et al. [22] . Recombinant lectins were conjugated with Biotin using the EZ-Linkۛ NHS-PEG 12 -Biotin system (Thermo Fisher Scientific) according to manufacturer's suggestion. Lectins were stored in 4ЊC.
SDS-PAGE and lectin blotting
Proteins and recombinant lectins were run on gradient 4-12% Novex Tris-Glycine gels from Life Technologies (Grand Island, NY, USA) or 8% Bis-Tris ExpressPlus TM PAGE gel (GenScript). Molecular weight SeeBlue Plus2 Prestained protein standard (Thermo Fisher Scientific Inc., Waltham, MA, USA) or Odyssey R One-Color Protein MW marker from LI-COR (Lincoln, NE, USA) were used. Samples were heated for 5 min at 100ЊC in presence of 2-mercaptoethanol. Following SDS-PAGE, gels were stained with Coomassie Blue G250 staining (Bio-Rad, Hercules, CA, USA) or transferred to PVDF membrane for lectin blot. PVDF membrane was blocked using 1X Carbo-Free Blocking solution (Vector Laboratories) for 1 h. The blots were probed using 1 g/mL biotin-labeled lectin in PBS for 1 h, followed by 3-5 min PBS/0.1% Tween-20 washes. The bound lectin was detected using Streptavidin IRDye 800 (LI-COR). Gels and blots were scanned using a LI-COR Odyssey Imager.
Glycan microarray
Mammalian glycan array (version 5.2) was performed by the CFG-Emory University, Atlanta, GA, USA under R24 GM098791 glue-grant from National Institute of General Medical Sciences (NIGMS) Large-Scale Collaborative Project Award. An array containing 609 biologically important glycans were printed in triplicate on NHS-activated slide. Biotinylated recombinant lectins at 50 and 5 g/mL were used and detected by 5 g/mL cyanine-5 streptavidin. For cyanine-5 detection, a ProScanArray microarray scanner with excitation at 649 nm and emission 670 nm was used. The scanned image was analyzed with ScanArray Express software. Data were normalized to percentage of the highest RFU to each glycan at each lectin concentration to obtain average binding. Data presented are average signal intensity and error bars indicate SD. Data collected from this experiment are available open-access for scientific community under CFG request# 3101. Detailed methods are found in Song et al. [23] .
Surface plasmon resonance
The SPR measurements were performed using a Biacore 3000 (GE Healthcare) instrument at 25ЊC with running buffer (10 mM HEPES, 150 mM NaCl, 0.005% v/v Tween 20, pH 7.4) at a flow rate of 20 L/min. To determine the binding preferences, the direct binding setup was chosen. The carboxymethyldextran surface of the CM5 chip was activated with EDC (N-ethyl-N- [3-dimethylaminopropyl] carbodiimide)/NHS (Nhydroxysuccinimide) solution using the standard manufacturer's protocol. Native AAL (Vector Laboratories) or recombinant N2224Q in 5 mM MES/NaOH, pH 6.0 buffer were repeatedly injected at a flow rate of 5 L/min into the flow channel until the relative response of immobilized protein reached app. 3000 RU. Finally, the sensor surface was blocked with 1 M ethanolamine. The blank channel was treated similarly, except for the lectin injection. L-Fucose (SigmaAldrich), Fuc1-2Gal, Fuc1-3-N-acetylglucosamine (Fuc1-3-GlcNAc), Fuc1-4GlcNAc, and Fuc1-6GlcNAc (all Carbohydrate Synthesis) were dissolved in the running buffer and 80 L of carbohydrate solutions with increasing concentrations were injected into the flow cells using Inject mode. Each experiment was performed in multiplicates. The equilibrium response (after subtracting the response of the reference surface) of each experiment was used to create analyte binding curves. Using the software Origin 7.0 (OriginLab Corp.), the data obtained for a particular ligand (all applicable runs) were simultaneously fitted applying common K d for all datasets. The steady-state affinity model was used, based on equation:
, where R is the detector response, R max is the maximal response, K d is the dissociation constant, and c(ligand) is the actual concentration of injected ligand.
Cell culture of cBAL111 and primary human hepatocytes
cBAL111 fetal liver hepatocytes were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) supplemented with 10% heatinactivated FBS (Corning); 1 M Dexamethasone (Sigma); 6.7 ng/mL of a mix containing insulin, transferrin, selenium, and 100 U/mL penicillin; and 100 g/mL streptomycin (Corning). Cells were grown at 37ЊC in the presence of 5% CO 2 . These cells were grown to confluence in 225 cm 2 tissue culture flasks (Corning), washed twice with PBS and serum-free media, and then placed into serum-free media for 24 h. The secreted proteins were collected and filtered through 0.45 m syringe filter, and buffer exchanged into PBS using Amicon Ultra-15 centrifugal filter units with 10 kD molecular weight cutoff (Millipore) at 4000 × g at 4ЊC in swinging bucket rotor of Eppendorf 5804R centrifuge.
Glycan sequencing
N-Glycans from 250 g of protein was released by overnight incubation of 30 U PNGase F and purified using HyperSep Hypercarb porous graphitic carbon columns and dried down by SpeedVac TM vacuum concentrators (Thermo Fisher Scientific). Cleaned N-glycans were labeled fluorescently with 2-aminobenzamide and separated on normal phase Waters Alliance HPLC system as previously described [21] [22] [23] [24] [25] [26] . Additionally, samples were subjected to exoglycosidase digestion (mannosidase, sialidase, fucosidase, and galactosidase, sequentially) for calculation of glucose unit (GU) value and compared to GlycoBase 3.2.4 database (National Institute for Bioprocessing Research and Training, Dublin, Ireland).
Lectin enrichment
Two hundred and fifty micrograms recombinant His-tagged AAL N224Q was bound to PureProteome TM Nickel magnetic beads (EMD Millipore) according to manufacturer's instructions. Secreted proteins from cBAL111 were collected in a serum-free media, concentrated using a 10 K buffer exchanged into PBS and 250 g of protein incubated with the N224Q-bead slurry overnight at 4ЊC. Unbound fractions were collected through a series of TBS washes and pooled. Bound proteins were eluted with 200 mM L-(-) Fucose (Sigma). Unbound and bound fractions were concentrated and buffer exchanged into TBS using a 10 000 molecular weight cutoff spin filter (EMD Millipore) at 10 000 × g at 4ЊC. Bound and unbound samples were prepared for MS sequencing.
Biotin-labeled PhoSL (250 g) was bound to 95 L of streptavidin-agarose beads according to manufacturer's instructions. Human sera, 20 samples each of cirrhotic and HCC, were pooled, protein A/G depleted of IgG, and incubated with PhoSL-agarose slurry. Unbound proteins were collected through a series of TBS washes, collected and pooled. The bound fraction was eluted using 200 mM Fucose with 48 h incubation at 4ЊC. Unbound and bound fractions were buffer exchanged with PBS as mentioned above.
Mass spectrometry
Protein concentrations from bound and unbound lectin pools were determined by Bradford Assay and 1.5 g of protein was digested with trypsin as described elsewhere [24, 25] . Trypsin digested peptides were concentrated and desalted using ZipTip C18 (Millipore) according to manufacturer's protocol. Prepared samples were analyzed by the Biological Mass Spectrometry Facility at Rutgers, the State University of New Jersey (Piscataway, NJ, USA) using a Velos LTQ Orbitrap tandem mass spectrometer coupled to a Dionex Ultimate 3000 RLSCnano System (Thermo Scientific). Samples were solubilized in 5% ACN/0.1% TFA, and loaded on to a fusedsilica trap column of 100 m × 2 cm packed with Magic C18AQ, 5 m 200Å (Michrom Bioresources Inc, Auburn, CA, USA). After washing for 5 min at 10 L/min with solvent A (0.2% formic acid), the flow rate was reduced to 300 nL/min and the trap brought in-line with a homemade analytical column (Magic C18AQ, 3m 200 A, 75 m × 50 cm) for LC-MS/MS. Peptides were eluted using a segmented linear gradient from 4 to 90% B (B: 0.08% formic acid, 80% ACN): 4% B for 5 min, 4-15% B for 19 min, 15-25% B for 40 min, 25-50% B for 55 min, and 50-90% B for 8 min. MS data were acquired using a data-dependent acquisition procedure with a cyclic series of a full scan acquired in Orbitrap with resolution of 60 000 followed by top 20 peaks fragmented and scanned in linear ion trap with a repeat count of two and the dynamic exclusion duration of 60 s. The LC-MS/MS data were searched against the most up-to-date human complete protein database (ensembl.org) using a local version of the Global Proteome Machine (GPM cyclone, Beavis Informatics Ltd., Winnipeg, Canada) with carbamidoethyl on cysteine as fixed modification and oxidation of methionine and tryptophan as variable modifications using a 10 ppm precursor ion tolerance and a 0.4 Da fragment ion tolerance.
Lectin fluorophore-linked immunosorbent assay
Briefly, 100 ng/well of the capture antibody (rabbit antifibronectin, Abcam, Cambridge, MA, USA) was incubated with sodium carbonate buffer, pH 9.5 overnight at 4ЊC in a 96-well Thermo Sceintific TM Maxisorp TM plate (Waltham, MA, USA). Following anti-Fibronectin antibody incubation, the plate was washed in PBS with 0.1% Tween-20. Nonspecific interaction was blocked using 1X Carbo-free blocking buffer (Vector Laboratory) overnight at 4ЊC. The next day samples were added and incubated for 30 min at 37ЊC followed by five washes using PBS/0.1% Tween-20. Biotinylated N224Q (1:5000) was added and incubated for 30 min at 37ЊC. Following lectin incubation, plates were washed as for the previous step, followed by 1:5000 dilution of Streptavidin IRDye800 (LI-COR) for 30 min in the dark at room temperature. Excess streptavidin IRDye800 was washed away with PBS/0.1% Tween-20. Plates were scanned using LI-COR Odyssey CLx (LI-COR) at the same intensity.
Results
In an effort to create fucose-binding lectins with increased specificity and sensitivity, we constructed recombinant (r)AAL molecules containing specific point mutations and domain changes [21] . Briefly, structural analysis of AAL [18] [19] [20] has shown that the 2 and 4 binding sites have glutamine (Q) residues in their fucose-binding pockets that coordinate with other amino acids within the pocket to maintain a secondary structure required for high-affinity fucose binding. In binding sites 3 and 5, an asparagine (N) is found in this position. As the side chain on N is one carbon shorter than Q, the 3 and 5 binding sites lack critical hydrogen bond contacts required for high-affinity fucose binding [19] . Thus, we changed the 224 asparagine in binding site 5 to glutamine to create rAAL N224Q. This mutation was predicted to increase the hydrogen bonding potential of the 5 site for fucosecontaining targets. This protein was expressed in Escherichia coli as His-tagged protein and purified via a two-column FPLC IMAC procedure which yields >90% pure fucose-free rAAL. Figure 1A shows an SDS-PAGE Coomassie stain analysis of wild-type AAL purchased from Vector Laboratories (36 kD), purified wild-type rAAL-10XHis, and the rN224Q mutant. The larger size of rAAL-10XHis and rN224Q is due to the C-terminal 10XHis tag on the recombinant lectins. In addition, the novel PhoSL [22] , which specifically recognizes ␣-1-6 fucosylation (core-fucosylation) was synthesized but not examined via SDS-PAGE, as it was too small (4.5 kD) to be observed on this gel (data not shown).
Figures 1B-E show the use of these lectins as affinity reagents in a lectin blot. Figure 1B shows the target antigens analyzed by lectin-Western. Target antigens shown in Fig. 1B included human IgG (with only a single ␣-1,6 linked fucose), BSA conjugated with ␣-1,3 linked fucose, BSA conjugated with galactose, and cord blood purified AFP, which contains only ␣-1,6 linked fucose [21, 26] . In all cases, 10 g of target antigen was resolved via SDS-PAGE and detected using 1 g/mL of lectin. As Fig. 1C shows, wild-type AAL binds all fucose linkages regardless of linkage. In contrast, the N224Q mutant had strong binding to the ␣-1,6 fucosylated IgG and AFP but very weak binding to the ␣-1,3 linked fucosylated glycoproteins (Fig. 1D) . This was similar to the PhoSL lectin, which had binding to the core fucosylated IgG and weaker binding to core fucosylated AFP and no binding to the ␣-1,3 linked fucosylated glycoproteins [22] . It is noted that limited washing (1x) of blots retained binding of the rN224Q lectin to the ␣-1,3 linked fucosylated glycoproteins, but this was lost with repeated washings (3x). This is consistent with the idea that N224Q, like what has been reported for Aspergillus oryzae L-fucose-specific lectin, has irreversible binding to core fucosylated glycan [27] .
SPR measurement was used to determine binding affinity of AAL and N224Q toward L-fucose and fucosylated disaccharides ( Table 1) . The results for AAL were consistent with previously published affinity [18] and revealed only minor differences in overall affinity for disaccharides containing L-fucose in ␣1-2, ␣1-3, ␣1-4, and ␣1-6 linkages. The same was observed for N224Q, although slightly higher affinity for tested sugars was determined. This confirms the ability of N224Q to bind various fucosylated ligands. Consequently, it suggests that the reported N224Q preference for core fucose might be revealed only in case of more complex oligosaccharides. The N224Q lectin, as it showed promise as core fucosebinding lectin, was subsequently examined with the CFG glycan array. The binding of the N224Q lectin or the recombinant wild-type control (concentrations of 5 and 50 g/mL) was tested on Version 5.2 of the Array. Supporting Information Fig. 2 shows a comparison of the binding of 5 g/mL of either the rAAL (Supporting Information Fig. 2A ) or rN224Q lectin (Supporting Information Fig. 2B ) to the glycans on the array. At this lower concentration, only high-affinity binding of lectin to ligands are detected [28] . Signal intensities overall were higher for rN224Q. For both rAAL and the rN224Q, very limited binding to nonfucosylated glycan was observed at any lectin concentration (ࣘ20 RFU). Focusing on the N-linked structures, binding of rAAL and rN224Q was observed for Fuc␣1-2Gal, Fuc␣1-3GlcNAc, Fuc␣1-4GlcNAc, and Fuc␣1-6GlcNAc-linked oligosaccharides. As Fig. 2 shows, N224Q tended to exhibit greater signal intensity relative to rAAL, with N-linked glycan containing ␣-1,2, ␣-1,3, and ␣-1,4-linked glycans ( Fig. 2A) . In the case of ␣-1,6 N-linked glycans, an even greater preference in the binding of N224Q versus rAALwas observed (Fig. 2B) . The mean of the fold increased binding of N224Q for noncore fucose-containing N-linked structures was 3.3 (range 0.7-8.3), whereas the fold increased binding for the core fucose-containing structures was 23.7 (range 0.4-69.4). This bias for the N224Q lectin is consistent with that observed by SPR (Table 1) .
Many biomarkers of cancer are fetally expressed genes that are derepressed, or overexpressed, in cancer cells. AFP, for example, has long been associated with HCC. Importantly, this molecule also becomes core fucosylated in HCC [29] .Thus, we reasoned that other such oncofetal proteins might also become core fucosylated. To test this possibility, the glycosylated proteins produced by a human fetal hepatocyte cell lines were characterized. The cell line cBAL111 was established by using human telomerase reverse transcriptase to immortal- ize human fetal hepatocytes [30] . These cells were described as being positive for both albumin and AFP. Cells were cultured as described in the Materials and Methods section, and then transferred into medium lacking serum or other protein supplements. After 24 h, supernatants and cell lysates were collected and protein-associated N-linked glycans were released enzymatically using PNGase F. After labeling the sugars at the reducing end with 2-aminobenzamide dye individual glycan species were separated by neutral-phase HPLC [6, 10, 14] . Glycan profile chromatograms are shown in Fig. 3 . A standard curve using the homopolymer dextran to convert elution time into GUs is shown at the bottom of the figure.
The glycan profile reveals the total released N-glycans present in the supernatant. Below, a series of sequential exoglycosidase digestions were performed to identify the individual glycans present in the supernatant (Fig. 3A) . Treatment with sialidase revealed that multiple species contained terminal sialic acid residues (Fig. 3A , second chromatogram from the top). Sialic acid removal simplified the profiles and allows us to conclude that the most abundant species in the cBAL111 supernatant is a triantennary A3G3 (GU 8.46) glycan that contributed 51.5% of the total profile. Treatment with almond meal fucosidase, which removes terminal ␣-1,2-and ␣-1,3-linked fucose residues did not change the profile, implying a lack of structures containing these fucosylated glycan. In contrast, treatment with bovine kidney fucosidase removed peaks at GU 7.63, representing a biantennary glycan with a core ␣-1,6-linked fucose(F (6) A2G2) that contributed 13.8% of the total glycan profile. Two minor species, representing core fucosylated tri-and tetra-antennary structures, were also reduced in height by this enzymatic treatment, although the tetra-antennary structure may have been incompletely digested. In summary, the analyses reveal that slightly more than half of the total glycan secreted by cBAL111 is a triantennary nonfucosylated structure. This is followed by the nonfucosylated and the fucosylated biantennary structures, each representing approximately 13% of the total glycan profile. It is interesting to note that glycan analysis of the cBAL111 cell lysate is very similar (Fig. 3B) . However, this is in sharp contrast to what is seen in primary human hepatocytes (Fig. 3C) , which primarily secrete proteins with N-linked biantennary nonfucosylated structures.
Based on the presence of core fucose present in the cBAL111 supernatants, we reasoned that fucose-binding lectins could be used to capture and identify fucosylated proteins. Based on its preferential binding (Table 1 and Fig. 2 ) the rAAL variant N224Q was chosen to be used as an affinity reagent for isolation of protein from cBAL111 supernatant, as we have done previously [31] ; the workflow is diagrammed in Supporting Information Fig. 2 . Both bound and unbound fractions were collected, digested with trypsin, and subjected to LC-MS/MS analysis as we have done previously [10] . A complete list of all the glycoproteins that were enriched in the N224Q bound fraction versus the unbound fraction is shown in Supporting Information Table 1 . Thirty of the top identified proteins in the fucosylated secreted proteome of cBAL111 cells are shown in Table 2 . In this list, proteins such as Fibronectin (FN1), which has recently been shown to be found in the human serum fucosylated proteome [32] and Golgi-protein 73 (GOLM1), which was also originally identified as part of the human serum fucosylated proteome [15] , are found highlighting the potential value of the identified proteins as biomarkers of HCC. The peptide list used to identify proteins is found in Supporting Information Tables 2 (bound) and 3 (unbound).
As both SPR and glycan array data indicated that the N224Q lectin can bind noncore fucosylated glycan, at least under certain circumstances, we performed a secondary confirmatory proteomic study, on pooled sera from patients with liver cirrhosis or pooled sera from matched HCC patients (also with cirrhosis) using the core fucose-binding lectin PhoSL and subjected these samples to identical LC-MS/MS analysis. As Table 3 shows, nine of the identified proteins found as part of the fucosylated proteome from the fetal cell line were also found associated with the core fucosylated proteome in human HCC. The peptide list used to identify proteins is found in Supporting Information Table 4 . These are considered further in the Discussion section. Finally, the presence of fucose on fibronectin was demonstrated by lectin fluorophore-linked immunosorbent assay with capture of the protein on immobilized antifibronectin and detection with fluorescent lectin (Supporting Information Fig. 3 ). As we detected little noncore fucose in the cBAL111 supernatant, this result confirms the presence of core fucose on fibronectin, which accounts for its capture by lectin.
Discussion
We have described the production of a novel variant of a rAAL lectin with improved specificity for ␣-1,6-linked fucose relative to the wild-type lectin. Increased specificity was confirmed via lectin blotting ( Fig. 1 ) and glycan array (Fig. 2) . The improved affinity was confirmed by SPR, although some of the specificity seen with the glycoproteins may not be retained with the smaller disaccharides used in this assay. The wide range of binding seen via the glycan array may also represent more complex factors that contribute to glycan recognition by these lectins, and this is currently the subject of further study.
We used this reagent to affinity capture core fucosylated glycoproteins from the supernatant of a human fetal hepatocyte-derived cell line (Fig. 3) . AFP, one of the few biomarkers for HCC, is produced by the fetal liver cells [30] . Thus, we reasoned that other coregulated fucosylated proteins might also prove useful as biomarkers. Proteomic analysis of bound versus unbound proteins revealed enrichment for several known secreted glycoproteins ( Table 1) that have been associated with HCC, by us and by others. These include the proteins fibronectin [32] , complement C1 R subcomponent, complement C1 S subcomponent [10] , angiotensinogen (AGT) [10] , clusterin [20] , and GP73 [33] . We have previously reported on the association of differentially glycosylated clusterin (CLU, also known as Apo-J) with liver disease [8] . In that study, we did not observe changes in core fucosylation with HCC compared to normal or cirrhosis. Instead, a decrease in the level of ␤-1,4 triantennary glycan was associated with increasing disease severity. However, it is conceivable that a shift in core fucosylation at a single site is being detected with the PhoSL lectin in the HCC versus cirrhotic samples.
The most highly represented glycoprotein that fit the criteria of being bound to N224Q and elevated in HCC is fibronectin (FN1). The form produced by hepatocytes is secreted into the circulation and is typically present in plasma at 0.3 mg/mL. Thus, the protein itself is unlikely to be useful as a biomarker, but the core fucosylated form(s) has already shown potential as a biomarker of HCC [32] . Core fucose is much more prevalent on the cellular form of fibronectin versus the plasma form produced by normal adult hepatocytes [34] , perhaps reflecting the fetal origin of the cBAL111 cells. A truncated version of FN1, containing only 657 amino acids of the N-terminus of the protein, has been termed migration stimulating factor, and is considered an oncofetal form [35] . However, inspection of the fibronectin peptides detected revealed that most map more C-terminally. An isoform of FN1 has previously been described as being an "oncofetal" antigen, based on an antibody that recognizes a complex epitope comprising both protein and O-linked oligosaccharide in a region of the protein that undergoes alternative splicing [36] . Like fibronectin (FN1), fibulin (FBLN1), thrombospondin1 (THBS1), and laminin subunit gamma-1 (LAMC1) are large extracellular matrix glycoproteins. While fibulin has been reported to be core fucosylated [37] , only O-linked fucose has been reported for thrombospondin [38] , and to our knowledge, there have been no reports of laminin fucosylation. Changes in expression of all three have been associated with HCC [39] [40] [41] [42] . A glycoproteomics study of sera from HCC patients versus controls identified a reduction of thrombospondin1 with HCC [43] . Clusterin was also reduced in HCC in that study, along with C1R, whereas galectin-3 binding protein was increased in HCC along with AFP. We also detected more of the latter protein in HCC versus cirrhotic (Table 1) , but cannot distinguish between changes in protein level versus changes in amount of core fucose. Galectin-3 binding protein (LGALS3BP) was reported to be core fucosylated in plasma [37] , and at least one site of core fucosylation is specifically associated with HCC. Increases in the ligand galectin-3 also have been associated with HCC [44] . Galectin-3 recognizes the oncofetal Thomsen-Friedenreich disaccharide antigen [45] .
C1R and C1S are both components of C1, the first step in the classical complement activation pathway and have been previously identified as being part of the fucosylated serum proteome [10] . Similarly, AGT, a key constituent of the renin-angiotensin system [46] , was previously identified as part of the fucosylated serum proteome in HCC patients [10] . In addition, AGT has been linked to HCC in a mouse model of HCC [47] . Finally, low-density lipoprotein receptorrelated protein 1 is actually a membrane-anchored glycoprotein. However, it was detected in plasma [37] , suggesting that some is lost from the surface. That study also identified lipoprotein receptor-related protein 1 as being core fucosylated, consistent with our results. However, the very low representation in the HCC serum makes its use as a biomarker uncertain.
In conclusion, we have performed glycoproteomics analysis of a fetal liver cell line in an effort to identify potential biomarkers of HCC. Conformation of many of the identified proteins was made through the subsequent analysis of human sera from those with HCC. Studies are underway to determine the ability of these proteins to act as biomarkers of HCC. 
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